Resilience to Manufacture mRNA for Moderna’s COVID-19 Vaccine. SAN DIEGO & CAMBRIDGE, Mass.
--(BUSINESS WIRE)--National Resilience, Inc. (Resilience), a company seeking to build the world’s most advanced biopharmaceutical manufacturing ecosystem, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) medicines, today announced an agreement to manufacture drug substance for the Moderna COVID-19 vaccine. Under the terms of the multi-year agreement, Resilience will produce mRNA for the Moderna COVID-19 vaccine at its facility in Mississauga, Ontario in Canada, for distribution worldwide. Moderna SE Asia partner says regional vaccine supplies booked until year-end. Moderna and Tabuk Pharmaceuticals Partner to Commercialize its Vaccine in Saudi Arabia. Agreement also includes distribution of Moderna’s updated variant booster candidates & --(BUSINESS WIRE)--Jun. 11, 2021-- (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and (a fully owned subsidiary of Astra Industrial Group), a leading Saudi pharmaceuticals company, today announced an agreement to commercialize the Moderna COVID-19 Vaccine and future variant-specific booster candidates in .
Under the terms of this agreement, will hold the marketing authorization for the Moderna COVID-19 vaccine in . Beyond the Moderna COVID-19 Vaccine and Moderna’s updated variant booster candidates, the agreement also gives Tabuk the possibility to discuss opportunities to distribute other mRNA products if authorized in the future.
Aldevron (plasmid DNA supplier; North Dakota) & --(BUSINESS WIRE)--May 24, 2021-- (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and , the leading provider of high-quality plasmid DNA, mRNA and recombinant proteins necessary for vaccines, gene and cell therapy, gene editing and diagnostic applications, have announced their expanded collaboration in support of the Moderna COVID-19 Vaccine and additional programs in Moderna’s clinical development pipeline.
Specifically, will supply plasmid DNA to serve as the genetic template for generating the COVID-19 mRNA vaccine and other investigational programs in Moderna’s pipeline. “Aldevron has been a long-standing partner of . We appreciate their collaboration and their expertise in the biologics space,” said , Chief Technical Operations and Quality Officer of . “We look forward to our ongoing work with this expanded partnership.” VAV Lifesciences to supply key COVID vaccine ingredient to Pfizer, Moderna. Biopharmaceutical firm VAV Lifesciences has signed an agreement to supply phospholipids, a crucial ingredient in the mRNA-based COVID-19 vaccines, with an American contract development and manufacturing firm which makes vaccines for multinational pharma giants Pfizer-BioNTech and Moderna.
Mumbai-based VAV Lifesciences is the only domestic firm in the COVID-19 vaccine supply chain with this crucial ingredient. It can thus can play a vital role in the global mRNA-based vaccine supply chain, the company claimed in a statement. The deal will be executed through its subsidiary VAV Lipids, which has entered into the agreement with a US-based contract development and manufacturing organisation to manufacture and supply the synthetic phospholipids to be used to to make COVID-19 vaccines.
Rovi participa en la fabricación del principio activo de la vacuna de Moderna contra la Covid-19. GC Pharma (Korea; distribution) Moderna Manufacturing (Norwood, Massachussetts) March 2, 2020 We believe manufacturing plays a critical role in our value chain and ability to develop a new category of medicines.
After receiving our first positive clinical data in our infectious disease portfolio, we began building a dedicated in-house manufacturing facility in Norwood, MA, in expectation of significant ongoing pipeline expansion and the long lead time required to create appropriate infrastructure. At Norwood, our process development (“create”) and manufacturing (“make”) capabilities are co-located which enables us to move more quickly from idea to implementation. Read about our manufacturing facility and its capabilities in this new white paper, which details how Norwood’s flexibility, along with the integration of technical development and manufacturing, has allowed us to quickly pivot and support exploratory programs that require integration of new capabilities.
Transport. Lonza (Visp, Switzerland; Portsmouth, New Hampshire) Fill & finish.